leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...7475767778798081828384...235236»
  • ||||||||||  gemcitabine / Generic mfg.
    Journal:  Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine. (Pubmed Central) -  Oct 15, 2022   
    Cross-resistance was assessed in MIA-PaCa-2 GR cells to FIRINOX (5-fluorouracil (5-FU), irinotecan, and oxaliplatin)...These findings provide evidence for the potential role of SSV 2β and other SSVs in innate and acquired PDAC chemoresistance. We also show that the expression of SSVs is not affected by the type of chemoresistance, therefore targeting survivin splice variants in combination with chemotherapy could benefit a wide range of patients.
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Clinical, Review, Journal, BRCA Biomarker, PARP Biomarker:  Long-term response in advanced pancreatic adenocarcinoma - a case report and literature review (Pubmed Central) -  Oct 15, 2022   
    We also show that the expression of SSVs is not affected by the type of chemoresistance, therefore targeting survivin splice variants in combination with chemotherapy could benefit a wide range of patients. Identifying predictive factors and specific targetable mutations in patients with advanced pancreatic cancer is needed to be able to apply more individual and specific therapies in order to improve outcomes.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX. (Pubmed Central) -  Oct 14, 2022   
    Adjuvant therapy with 5-fluorouracil-based regimen [HR, 0.35 (95% CI, 0.15-0.84); p = 0.018], positive resection margin [HR, 4.14 (95% CI, 1.75-9.78); p = 0.001], presence of pathologic lymph node involvement [HR, 3.36 (95% CI, 1.23-9.15); p = 0.018], poor differentiation [HR, 5.69 (95% CI, 1.76-18.36); p = 0.004], and dose reduction during adjuvant therapy [HR, 1.78 (95% CI, 1.24-24.37); p = 0.025] were associated with decreased overall survival. The 5-fluorouracil-based adjuvant therapy seems to be the proper adjuvant therapy for patients who received neoadjuvant FOLFIRINOX for borderline resectable and locally advanced pancreatic cancer.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date:  Chemoradiation or Brachytherapy for Rectal Cancer (clinicaltrials.gov) -  Oct 14, 2022   
    P2,  N=138, Active, not recruiting, 
    Trial completion date: Dec 2024 --> Jun 2023 Trial completion date: Jun 2022 --> Jan 2023
  • ||||||||||  dilpacimab (ABT-165) / AbbVie
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) -  Oct 14, 2022   
    P1,  N=101, Completed, 
    Trial completion date: Jun 2022 --> Jan 2023 Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Sep 2022 | Trial primary completion date: Sep 2023 --> Sep 2022
  • ||||||||||  Renal Safety of FLOT Regimen for Gastroesophageal Cancer: Time for Break Boundaries? (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1979;    
    New onset anemia was the only significant adverse event observed (p=0.003). Conclusion Surprisingly, the pre-operative FLOT regimen seems to have a negligible impact on renal function suggesting the possibility to extend its use even in patient with advanced CKD.
  • ||||||||||  methotrexate IV / Generic mfg.
    High-Dose Methotrexate (HDMTX) Induced Nephrotoxicity: Glucarpidase or Dialysis? (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1069;    
    Discussion Routine monitoring of MTX levels can lead to early recognition of AKI.Glucarpidase is an enzyme that cleaves MTX into inactive metabolites providing an alternative route for elimination.Case reports describe successful treatment of AKI with its use in addition to leucovorin rescue, hyperhydration and urine alkalization.Our patient was treated successfully with the same regimen with absence of other MTX toxicities.In the above reports, there was no rebound in MTX levels after single dose Glucarpidase as seen in our patient also...Learning objectives Routine monitoring of MTX levels can lead to early recognition of AKI. Prompt intervention with Glucarpidase can successfully treat AKI with no rebound in MTX levels and eliminate the need for HD.
  • ||||||||||  Tibsovo (ivosidenib) / Servier
    Review, Journal, BRCA Biomarker:  Role of genetic testing in hepatic, pancreatic, and biliary cancers. (Pubmed Central) -  Oct 13, 2022   
    As a result, many national and societal guidelines now recommend some form of genetic testing in the workup of patients with HPB cancers. We herein review the role of genetic testing in these aggressive cancers including DNA sequencing techniques, clinically relevant mutations, therapeutic implications, and current clinical recommendations.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal, Real-world evidence, IO biomarker:  The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. (Pubmed Central) -  Oct 13, 2022   
    Cisplatin with gemcitabine is used as the standard first-line chemotherapy regimen; however, there is still no robust evidence for second-line and successive treatments...All patients received infusional 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) via HAIC until progression or unacceptable toxicity...Therefore, HAIC may be a promising and valuable complementary therapy for advanced CCAs as a second-line and successive therapy. Otherwise, the combination of HAIC with precision medicine may improve clinical benefits (clinical registration number: 2021BAT4857).
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker:  Immunotherapy in advanced gastric cancer (Pubmed Central) -  Oct 12, 2022   
    After initial therapeutic trials with mixed or even negative results, immunotherapy was able to make a breakthrough with the checkmate 649 phase III trial demonstrating a significant survival improvement by adding nivolumab to a first-line chemotherapy by XELOX or FOLFOX...The variation in the therapeutic response obtained by immunotherapy supposes the existence of molecular subgroups more or less sensitive to these immune checkpoint inhibitors. Some biomarkers have been identified as predictors of response to immunotherapy, such as microsatellite instability, which is probably the most robust of them, but also tumor mutational burden, lymphoplasmacytic infiltration, or EBV tumor positive.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma. (Pubmed Central) -  Oct 12, 2022   
    Some biomarkers have been identified as predictors of response to immunotherapy, such as microsatellite instability, which is probably the most robust of them, but also tumor mutational burden, lymphoplasmacytic infiltration, or EBV tumor positive. The addition of P-AscH - to standard of care chemotherapy has the potential to be an effective adjuvant for PDAC treatment.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Biomarker, Journal:  A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome. (Pubmed Central) -  Oct 12, 2022   
    SEC6-based risk stratification indicated that 5-FU treatment was beneficial for low-risk patients, whereas only aggressive treatments (FOLFOX and FOLFIRI) provided benefits to high-risk patients in stages II and III. In summary, this novel risk-score demonstrates the value of the secretome compartment as a reliable source for the retrieval of biomarkers with high prognostic and chemotherapy-predictive capacity, providing a potential new tool for tailoring decision-making in patient care.
  • ||||||||||  Journal:  Painful lower limb nodules as first symptom of resectable pancreatic acinar cell cancer: a case report. (Pubmed Central) -  Oct 12, 2022   
    In summary, this novel risk-score demonstrates the value of the secretome compartment as a reliable source for the retrieval of biomarkers with high prognostic and chemotherapy-predictive capacity, providing a potential new tool for tailoring decision-making in patient care. This case illustrates the importance of clinically recognizing cutaneous nodules and pathological recognizing the specific microscopic changes as sign of a (malignant) pancreatic disease.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    Retrospective data, Journal, MSi-H Biomarker, PD(L)-1 Biomarker:  Retrospective Analysis of Treatment Pathways in Patients With BRAF-mutant Metastatic Colorectal Carcinoma - MORSE. (Pubmed Central) -  Oct 10, 2022   
    Combined chemotherapy+TT (anti-VEGF/VEGFR and anti-EGFR) played a predominant role in BRAF-mutated mCRC treatment prior to approval of the targeted combination encorafenib plus cetuximab. Since lack of efficacy was the major reason for treatment discontinuation, newly approved therapies including encorafenib plus cetuximab and - for MSI-H tumors - pembrolizumab represent urgently needed options for future mCRC patients.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    A Case of Toxic Epidermal Necrolysis During Immune Checkpoint Inhibitor and Platin Treatment for Cancer (Exhibit Hall (Upper Concourse); Monitor 02) -  Oct 10, 2022 - Abstract #ACAAI2022ACAAI_836;    
    We present a case of metastatic gastroesophageal cancer treated with nivolumab and FOLFOX causing toxic epidermal necrolysis (TEN)...He received intravenous solumedrol, famotidine, and diphenhydramine and was discharged on a prednisone taper and topical triamcinolone...FOLFOX was subsequently discontinued and capecitabine was started...Patch testing is available but has little utility for TEN. Testing for platins with delayed reads along with 10-90 dosing may be useful to establish the safety of continued platin treatment.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer (Exhibition / Poster Area) -  Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_934;    
    Relative DI (RDI) for oxaliplatin, 5FU, irinotecan and leucovorin was 38%,36%,41% and 39% respectively...Conclusions Only 50% of patients completed the planned therapy with mFOLFIRINOX in our population. This has resulted in poor efficacy of the regimen.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Induction bio-chemotherapy or bio-chemoimmunotherapy for locally advanced betel-nut-related HNSCC in Taiwan (Exhibition / Poster Area) -  Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_758;    
    Bio(EGFR or VEGFR-targeting)-chemotherapy or bio-chemoimmunotherapy has brought encouraging induction response with favorable toxicity profiles to conversion surgery or definite CCRT. Further investigation and clinical trials will be urgently warranted.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    An open label pilot study to evaluate efficacy and safety of durvalumab with hepatic artery infusion chemotherapy (HAIC) in advanced hepatocellular (aHCC) patients with severe portal vein tumor thrombosis (PVTT) (Vp3 and/or Vp4): DurHope (Exhibition / Poster Area) -  Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_684;    
    P2
    Emerging evidence shows that selected patients with PVTT will have better survival and ORR benefit from HAIC versus sorafenib...Patients will administrated HAIC with modified FOLFOX6 regimens including (oxaliplatin 130 mg/m2 infusion for 3 hours on day 1, leucovorin 200 mg/m2 from hour 3 to 5 on day 1 and Fluorouracil 400 mg/m2 in bolus, and then 2,400 mg/m2 continuous infusion 46 hours; q3w; 4-6 cycles)...Durvalumab was given every 3 weeks during HAIC combination treatment (1120mg，Q3W) and every 4 weeks during durvalumab monotherapy(1500mg, Q4W) until disease progression or unacceptable toxicity. The primary endpoints will be 1 year OS rate; secondary endpoints include ORR and PFS by RECIST v1.1, safety; exploratory endpoint will be the relationship between the clinical efficacy and PD-L1 expression status.
  • ||||||||||  LABS score: The prognostic tool for advanced hepatocellular carcinoma treated with FOLFOX4 and real-world efficacy from a single-center retrospective study (Exhibition / Poster Area) -  Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_678;    
    Background There is no widely used prognostic tool to demonstrate the benefit of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) in patients with advanced hepatocellular carcinoma (HCC)...Four variables were included in the new prognostic score to predict 6-month overall survival based on their clinical relevance: L, the presence of lung metastasis; A, alcoholic cirrhosis; B, elevated total bilirubin; and S, sorafenib naive...Therefore, we suggest that FOLFOX4 should be considered as one of the options for those who cannot approach immunotherapy and targeted therapy, particularly with a low-risk score. However, this model should be further evaluated in the larger cohorts.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Efficacy and safety of mFOLFOX-6 in advanced gastric cancer: A prospective observational study (Exhibition / Poster Area) -  Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_673;    
    Conclusions mFOLFOX-6 is an active and well-tolerated chemotherapy regimen in advanced adenocarcinoma of stomach/GEJ. This regimen has similar response rates and treatment outcomes with lesser grade 3 or 4 toxicities than that of triplet regimens compared to historical studies.
  • ||||||||||  Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data (Exhibition / Poster Area) -  Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_672;    
    Common chemotherapy regimens used were FOLFOX in 45%, and paclitaxel/carboplatin combination in 37% of patients...Despite recent updates in esophageal cancer treatment and the inclusion of newer therapies over time, cost and availability of medications have limited the incorporation of the same in clinical practice in developing countries. There is an unmet need to improve outcomes in both early and advanced stage esophageal cancers.